Clinical Research
Contact Information
Saifee Hospital -
02269515253, 02267571228, 02267571229
Wockhardt Hospital -
02261784444
Jaslok Hospital -
02266573014, 02266573076, 02266573200
Phone :
Mobile - 9820747496 (For Emergency)
Residence Tel: (+91)2223516880
Email :
rahulchakor@gmail.com, drchakorrt@yahoo.co.in
| Epilepsy Center Cleveland Clinic, USA |
|---|
| Research experience as a research fellow in Clinical Neurophysiology/EEG and Epilepsy at the Epilepsy Center, Department of Neurology, Cleveland Clinic Foundation, USA from September 24th, 2007 to March 25th, 2008. |
| Cleveland clinic neurophysiology/eeg course |
|---|
| Successfully completed the Cleveland clinic Neurophysiology/EEG Course from September 24th 2007 to December 14th 2007. Following the course worked in the Adult Epilepsy Monitoring unit from December 15th 2007 to February 2nd 2008. Worked in the Pediatric and Neonatal Epilepsy Monitoring Unit from February 3rd 2008 to March 25th 2008. |
| International League Against Epilepsy, European Epilepsy Academy Course |
|---|
| EEG in the diagnosis & management of epilepsy course, International League Against Epilepsy, European Epilepsy Academy from October 15 2010 – May 22, 2011. |
| Clinical Antiepileptic Drug Pharmacology course, European Epilepsy Academy, October 30 2009- June 10 2010 |
| Research experience for clinical trials and drug research |
|---|
| Principal Investigator, COMB157G2302, ASCLEPIOS, A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis |
| Principal Investigator, EMPOwER Protocol, A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous 70 mg or 140 mg AMG 334 against placebo in adult episodic migraine patients |
| Principal Investigator, An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis. |
| Principal Investigator, A prospective, multi–centric single arm, clinical study to evaluate efficacy and safety of R-TPR -004 in patients undergoing treatment for acute ischemic stroke |
| Principal Investigator, A multicentric, open label, two treatment, two period, two sequence, multiple dose, cross-over, steady state bioequivalence study comparing Pramipexole, oral prolonged release tablet 3.15 mg (Actavis inc.), to IP oral tablet 3.15 mg in patients with idiopathic Parkinson`s disease |
| Principal Investigator, A prospective, multicentric, double-blind, randomized, phase III clinical study to compare the efficacy and safety of intravenous Kallikrein versus placebo along with standard supportive care in treatment of mild to moderate ischemic strokes. |
| Principal Investigator, Prospective randomized 12-week controlled study of visual Field change in subjects with partial seizures receiving Pregabalin or placebo |
| Subinvestigator, A Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of Investigational drug in Subjects with Relapsing-Remitting Multiple Sclerosis |
| Subinvestigator, An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of Investigational drug in subjects (≥ 16 to 70 years old) suffering from localization-related or generalized epilepsy |
| Subinvestigator, An Open label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of Investigational drug used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy |
| Subinvestigator, Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with Investigational drug in patients with a history of ischaemic stroke or transient ischaemic stroke - The PERFORM study |
| Subinvestigator, A Randomised, Double-blind, Placebo-controlled, Parallel-Group, Multicentre study to Evaluate the Efficacy, Safety, and Tolerability of Investigational drug as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-label Extension study |
| Subinvestigator, Effect of g-Secretase Inhibition on the Progression of Alzheimer’s Disease |
| Subinvestigator, A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s disease treated with a stable dose of a single dopamine agonist. |
| Subinvestigator, A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as an add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine |
| Subinvestigator, A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, with Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the Cogstate Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients Randomized to Either Donepezil or Placebo |